Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

4370 results

Sort By:

Clinical Feasibility & Validation of the Augmented Reality GlenxRose Acquired Brain Injury Rehabilitation Programs

Study ID: NCT05897593
Start Date: 2025-10-01
End Date: 2026-08-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

GlenXRose Augmented Reality Acquired Brian Injury Therapies

Sponsor

University of Alberta

Source: clinicaltrials.gov

Share:
Add to list

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Study ID: NCT07126561
Start Date: 2025-11-01
End Date: 2028-11-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

43

Intervention / Treatment

Trastuzumab Deruxtecan

Sponsor

University of Chicago

Source: clinicaltrials.gov

Share:
Add to list

Adapting the Penny Chatbot for Perinatal OUD Patients: COPILOT

Study ID: NCT06969261
Start Date: 2026-01-01
End Date: 2026-06-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Penny COPILOT

Sponsor

University of Pennsylvania

Source: clinicaltrials.gov

Share:
Add to list

Fibrinogen in Liver Transplant Subjects

Study ID: NCT06764927
Start Date: 2025-10-31
End Date: 2026-03-01
Study Type

Interventional

Study Phase

Phase4

No. of Participants

30

Intervention / Treatment

Cryoprecipitate Intercept Fibrinogen Complex (IFC)

Cryoprecipitate Antihemophilic Factor (AHF)

Sponsor

Ezeldeen abuelkasem

Source: clinicaltrials.gov

Share:
Add to list

Utility of a Mobile Application for Young Women With Breast Cancer

Study ID: NCT07009093
Start Date: 2025-12
End Date: 2030-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

120

Intervention / Treatment

Mighty Pro Application

Sponsor

Wake Forest University Health Sciences

Source: clinicaltrials.gov

Share:
Add to list

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Study ID: NCT07189793
Start Date: 2025-10
End Date: 2028-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

106

Intervention / Treatment

Tripleimab

Gemcitabine (Save)

Mitomycin C (MMC)

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Source: clinicaltrials.gov

Share:
Add to list

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Study ID: NCT07160205
Start Date: 2025-10
End Date: 2029-05
Study Type

Interventional

Study Phase

Phase3

No. of Participants

40

Intervention / Treatment

ULSC (1.5 x 10^8 cells/dose)

Placebo (no cells)

Sponsor

Let's subtract, llc.

Source: clinicaltrials.gov

Share:
Add to list

Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis

Study ID: NCT07188766
Start Date: 2025-10
End Date: 2026-10
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

394

Intervention / Treatment

Sodium Chloride (NaCl) 0.9 %

Sodium Chloride (NaCl) 0.9 %

Sponsor

Imam Abdulrahman bin Faisal University

Source: clinicaltrials.gov

Share:
Add to list

Safety and Efficacy of Linnea Safe PMMA 30% Use for Gluteal Augmentation.

Study ID: NCT06851494
Start Date: 2025-11-01
End Date: 2026-11-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

137

Intervention / Treatment

PMMA

Sponsor

Lebon Chemical Products and Pharmaceuticals Ltda.

Source: clinicaltrials.gov

Share:
Add to list

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Study ID: NCT07176975
Start Date: 2025-10-21
End Date: 2029-05-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

46

Intervention / Treatment

BI 1831169

Nivolumab

Sponsor

Boehringer Ingelheim

Source: clinicaltrials.gov

Share:
Add to list